C-D7IUHumacyte Inc.
bioengineered tissues, decellularization, regenerative medicine
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-D7IU
C-D7IUC-D7IUbioengineered tissues, decellularization, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Most Investors STILL Don’t See This About Humacyte (HUMA) Humacyte (HUMA) is continuing to build momentum following the FDA approval of Symvess, with growing military, institutional and international validation. In this video, I examine the Pentagon interest, VA hospital contract access, Ukraine battlefield results and expanding global discussions in Israel and Saudi Arabia. I also discuss why many investors may still be underestimating the long-term strategic potential of Humacyte despite adoption likely taking time. #humacyte #huma #humastock #symvess Disclaimer This video is for educational and entertainment purposes only and is not investment advice. I am purely documenting my opinions on companies that interest me. I am not a Financial Advisor and I am not your Financial Advisor. You risk losing your money by investing. Please do your own due diligence and get advice from an expert. I am human and get things wrong. Tags Humacyte, HUMA, $HUMA, Humacyte Stock, HUMA Stock, Humacy
Humacyte Stock Collapsed… But The Real Story May Just Be Starting for HUMA Humacyte (HUMA) stock analysis and why the market may be underestimating Symvess. In this video we break down Humacyte stock, recent dilution concerns, FDA approval progress, commercialization challenges, and the long-term potential for HUMA stock as adoption of Symvess continues to expand. #humacyte #huma #humastock #symvess Disclaimer This video is for educational and entertainment purposes only and is not investment advice. I am purely documenting my opinions on companies that interest me. I am not a Financial Advisor and I am not your Financial Advisor. You risk losing your money by investing. Please do your own due diligence and get advice from an expert. I am human and get things wrong. Tags Humacyte, HUMA, $HUMA, Humacyte Stock, HUMA Stock, Humacyte Stock, biotech stocks, biotech investing, pharma stocks, pharma investing, pharmaceutical stocks, pharmaceutical investing, biotech news, pharma news
In this video i will go over #huma news! #huma news https://www.globenewswire.com/news-release/2026/05/20/3298432/0/en/humacyte-announces-symvess-is-now-under-contract-with-the-strategic-acquisition-center-sac-of-the-u-s-department-of-veterans-affairs.html Find more stocks in my link tree watchlist ! https://linktr.ee/nicolejosephinedecor Not investment advice!
Humacyte (HUMA) posts 400% revenue growth — biotech stock analysis and valuation 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=youtube&utm_medium=explainer_video&utm_campaign=freja_and_friends In this deep dive, we break down Humacyte (HUMA) and its critical transition into a commercial-stage powerhouse with its revolutionary bioengineered human tissue platform. With Q1 2026 commercial revenue jumping nearly 400% year-over-year but a cash runway warning of under 12 months, the key question for investors is whether clinical adoption and the upcoming Phase III dialysis catalyst can outpace the cash burn. Here’s everything you need to know before making a decision on HUMA. 🎯 SECTIONS: • The Bioengineering Framework: How ATEV Technology Works • Symvess Clinical Performance & Vascular Trauma Market • The Arteriovenous Dialysis Catalyst (V012 Phase III Trial) • Q1 2026 Commercial Execution & Hospital Pe
An educational short guide showing how to buy shares of Humacyte Inc (HUMA). Learn the practical steps to locate and purchase Humacyte stock using a popular broker. https://med.etoro.com/B19645_A127973_TClick_Sinvesting_step_by_step_youtube.aspx Affiliate link. I may receive a commission if you register through this link at no additional cost to you. Humacyte Inc is a biotechnology company focused on developing bioengineered human acellular vessels and regenerative medicine treatments. In this short tutorial we cover the basic steps to buy Humacyte shares: register with a broker, verify your account, deposit funds, search for the HUMA ticker, confirm the correct NASDAQ listing, and place a buy order. Step summary: 1) Open an account with a regulated broker (we use eToro as a neutral example). 2) Complete ID verification and add funds to your account. 3) Use the platform search to find the HUMA ticker listed on NASDAQ and open the stock page. 4) Select an investment amount, review t
Should you invest in Humacyte right now? I analyze the business and determine the intrinsic value of the stock. #investing #stocks #stockstobuy #beststocks #stocksinthenews ⭐Join My Patreon: https://www.patreon.com/growthshares ⭐Take My Quiz: https://youtu.be/Kcqo_5FAp2w ⭐Get $5 FREE to Spend Online (Affiliate): https://app.privacy.com/join/T7UUH ⭐Subscribe to GrowthShares: https://www.youtube.com/channel/UCcIfqL77FTgHcFRvgJCrFhw?sub_confirmation=1 ⭐I may or may not have a financial interest (investment) in this company before or after the publication of this video. #GrowthShares #StockAnalysis **NOT FINANCIAL OR INVESTMENT ADVICE. DO YOUR OWN RESEARCH** Disclaimer: The content in this video and this channel are for educational purposes only. I'm not a financial advisor and it is your responsibility to do your own research before making any decision when it comes to your money and your life. This does not constitute investment advice of any kind. Affiliate Disclaimer: Some of
Humacyte Class Action Lawsuit: HUMA Shareholders Allege Stock Artificially Inflated when Purchased The Humacyte class action lawsuit seeks to represent purchasers or acquirers of Humacyte, Inc. (NASDAQ: HUMA) securities between May 10, 2024, and October 17, 2024, inclusive (the “Class Period”). Captioned Cutshall v. Humacyte, Inc., No. 24-cv-00954 (M.D.N.C.), the Humacyte class action lawsuit charges Humacyte and certain of Humacyte’s top executives with violations of the Securities Exchange Act of 1934. If you have suffered losses in Humacyte stock and are interested in becoming the lead plaintiff in the Humacyte class action lawsuit or have any inquiries regarding your rights as a shareholder, please reach out to Humacyte Stock Loss Lawyer Timothy L. Miles at no cost. You can contact him by calling 855/846-6529, sending an e-mail to [email protected], or filling out a contact form below. Lead plaintiff motions for the Humacyte class action lawsuit must be filed with the co
You may not have seen it, but something happened while we were all in holiday shopping mode that might just change the world. A Durham company filed an application with a federal government agency. That company and the product behind its application could revolutionize medical care for certain patients and save countless lives in the future.
Humacyte’s human acellular vessels are experimental, engineered, off-the-shelf replacement vessels that are being developed for vascular repair, reconstruction, and replacement. The vessels are designed to overcome long-standing limitations in vessel tissue repair and replacement. Though not yet approved, the manufactured vessels are getting a real-world test as the company has been providing them to hospitals in Ukraine to treat wounded civilians and soldiers with vascular injuries. We spoke to Laura Niklason, CEO of Humacyte, about the company’s human acellular vessels, how they are produced, and the potential needs they can address.
The goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the ATEV and AVF groups over 12 months in patients with end-stage renal disease (ESRD) needing hemodialysis (HD). Participants will be stratified by location of the vascular access (forearm versus upper arm) and by type of AVF creation procedure planned by the surgeon at randomization (1-stage AVF versus 2-stage AVF). The comparator is an upper extremity arterio-venous fistula (AVF) for HD access surgically created per the institution's Standard of Care (SoC).
This is Move The Needle with Rob Kaplan, where we talk to people who lead, innovate, and inspire. Today on Move The Needle, Rob talks with former Kansas governor and Health and Human Services secretary Kathleen Sebelius, who has spent her entire life in and around politics. Kathleen Sebelius is one of America’s foremost experts on national and global health issues, human services, and executive leadership. As CEO of Sebelius Resources LLC, she provides strategic advice to companies, investors, and non-profit organizations. Sebelius chairs the board of Humacyte and serves on the boards of directors of Devoted Health, Exact Sciences, Included Health, and the Kaiser Family Foundation. She co-chairs the Aspen Institute Health Strategy Group and serves on advisory boards for the Dole Institute of Politics, Solera Health, Out Leadership, the Estée Lauder Foundation, Protect Our Care, the University of Kansas College of Liberal Arts and Sciences, and Zipline. Sebelius is honorary co-chair a
Human Acellular Vessels are bioengineered blood conduits which have shown great promise in clinical trials for vascular applications, including arteriovenous access for hemodialysis, peripheral arterial disease, and trauma repair. Dr. Laura Niklason, Founder and CEO of Humacyte, discusses this promising technology and its recent deployment as humanitarian aid for repairing vascular trauma in Ukraine.
Humacyte provided HAVs as humanitarian aid to Ukraine. This retrospective observational study is designed to collect data from patients in whom the HAVs have already been implanted on a humanitarian basis between June 2022 and May 2023.
2:33 Labiotech.eu news 5:03 Humacyte 23:01 Transgene 37:21 Center for Global Development 54:32 JLL This week, there are three interviews. One is from Bio-Europe, and it’s a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance. We also have our weekly commentary from Travis McCready at JLL. About Labiotech.eu: Labiotech.eu is the leading digital media covering the European Biotech industry. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories! Facebook: https://www.facebook.com/Labiotech.eu Twitter: https://twitter.com/Labiotech_eu Linkedin: https://www.linkedin.com/company/labi... Instagram: https://www.instagram.com/labiotech.eu Meetup:https://www.meetup.com/Labiotech-Meetup/
✅ Get inspired by Women Leaders in Tech 😍 ✅ Connect with Experts 🧑🏽💼 ✅ Find New Answers 💫 ✅ Have More Impact 🗣️ ✨ WITI Hall of Fame Inductee ✨ ⭐ 👋🏼 Meet Laura Niklason, one of WITI's Hall of Fame #Inductees, she is the #founder of the regenerative medicine company @Humacyte and a professor of anesthesiology and biomedical engineering at @YaleUniversity. ⭐ Laura’s #bioengineered blood vessels are currently undergoing #clinicaltrials, and are the first life-sustaining #engineered tissues to be studied under a Phase III trial.✨ 🚨 If you’re looking to advance your career, be briefed on the latest advances in your area of expertise and network, and connect about new career opportunities! 🚨 💫 Join leading women in tech and visit https://witi.com/ #WITI #TechHistory #WomenMakingaDifference #HerStory #womenintech #FemalesInTech #LauraNiklason #YaleUniversity #Humacyte #regenerativemedicine #stemcelltherapy #stemcell #medicine #health #wellness #painrelief #functionalmedicine
Humacyte CEO Dr. Laura Niklason Investor Presentation March 2021
Leadership Lounge, Episode 5: Todd Sears & Secretary Kathleen Sebelius Broadcast date: Wednesday, May 13 @ 1pm For this episode Out Leadership's Founder & CEO Todd Sears was joined by one of America’s foremost experts on national and global health issues, human services, and executive leadership, the former (from 2009 until 2014) United States Secretary of Health and Human Services, Kathleen Sebelius -- who was instrumental in overseeing the implementation of the Affordable Care Act. Kathleen Sebelius Former Secretary of Health and Human Services United States of America Kathleen Sebelius is one of America’s foremost experts on national and global health issues, human services, and executive leadership. As CEO of Sebelius Resources LLC, she provides strategic advice to companies, investors, and non-profit organizations. Sebelius serves on the boards of directors of Dermira, Devoted Health, Exact Sciences, Grand Rounds, Humacyte, the Kaiser Family Foundation, and Myovant Sciences.
This is a Phase 2, prospective, multicenter, open-label, single-arm study of the Human Acellular Vessel (HAV).
This study evaluates the use of the Human Acellular Vessel (HAV) in adults with vascular trauma below the neck who are undergoing vascular reconstructive surgery. There will be a torso cohort and a limb cohort. All subjects will be implanted with a HAV as an interposition vessel or bypass using standard vascular surgical techniques. There is no control arm.
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access
This study will evaluate how well Humacyte's Human Acellular Vessel (HAV) works when surgically implanted into a leg to improve blood flow in patients with peripheral arterial disease (PAD). This study will also evaluate how safe it is to use the HAV in this manner.
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.
The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vessel (HAV). The HAV is intended as an alternative to synthetic materials and to autologous grafts in the creation of an above-knee femoro-popliteal bypass graft in patients with peripheral arterial disease.
The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vascular Graft, HAVG. The HAVG is intended as an alternative to synthetic materials and to autologous grafts in the creation of vascular access for dialysis.
The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vascular Graft, HAVG. The HAVG is intended as an alternative to synthetic materials and to autologous grafts in the creation of vascular access for dialysis.
Humacyte Combines with Alpha Healthcare in Latest Biopharma SPAC - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Humacyte Combines with Alpha Healthcare in Latest Biopharma SPAC August 27, 2021 | 3 min read | Mark Terry Twitter LinkedIn Facebook Email Print Laura Niklason, Founder, President & CEO of Humacy The combined company out of the Humacyte SPAC will be called Humacyte and is exp … actice of medicine. With a validated HAV platform technology and vast potential application, compelling data, a well-defined regulatory pathway, and scalable, proprietary commercial-scale manufacturing capability, Humacyte has all the ingredients to revolutionize patient care.” Twitter LinkedIn Facebook Email Print Earnings Mergers & acquisitions Food and Drug Administration (FDA) Mark Terry LATEST Layoff Tracker Genentech R&D cuts include longtime top exec June 12, 2 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell an … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp. August 26, 2021 | 9 min read Twitter LinkedIn Facebook Email Print Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue a … said Ms. Sebelius. “With a validated HAV platform technology and vast potential application, compelling data, a well-defined regulatory pathway, and scalable, proprietary commercial-scale manufacturing capability, Humacyte has all the ingredients to revolutionize patient care. It’s been an honor to serve on Humacyte’s Board for the past six years, and I now look forward to leading the Board and collaborating with the Humacyte leadership team in the important work ahead.” Tran … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Individual patient expanded access requests may be considered for patients who have no other treatment options and are not eligible for an ATEV clinical study
Individual patient expanded access requests may be considered for patients who have no other treatment options and are not eligible for an ATEV clinical study.
Loading... HUMACYTE INC Earnings Call Transcript FY25 Q2 Back HMCY HM HUMACYTE INC ( HUMA ) Q2 2025 Earnings-Transcript Follow Summary Share AI Assistant Summary AI Assistant FY 2026 Q1 14 May '26 FY 2025 Q3 13 Nov '25 FY 2025 Q2 12 Aug '25 FY 2025 Q1 14 May '25 FY 2024 Q4 1 Apr '25 FY 2024 Q3 11 Nov '24 FY 2024 Q2 14 Aug '24 FY 2024 Q1 13 May '24 FY 2023 Q4 23 Mar '24 FY 2023 Q2 15 Aug '23 FY 2023 Q1 17 May '23 FY 2022 Q4 30 Mar '23 Title Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call Transcript Presentation Humacyte, Inc. misses … the Centers for Medicare and Medicaid Services, or CMS, declined to approve our application for the new technology add-on payment, or NTAP, for Symvess. Our application was submitted in October of 2024. And along with the majority of applications that were submitted to CMS this cycle, our application was also denied. The reason provided by CMS was that Symvess does not have a unique mechanism of action as compared to veins or synthetic grafts and therefore, did not qualify fo … ieved in April of 2025. Subject to these interim results, Humacyte’s plan is to submit a supplemental BLA in the second half of 2026, including data from V012 and the V007 Phase III pivotal studies to expand the Symvess label and add AV access for hemodialysis as an indication. We’re pleased with the progress that we’re making in 2025, and we look forward to sharing our progress with all of you as the rest of the year unfolds. With that, I’ll now turn it over to Dale for a re … ve that in — later in 2025 as we’ve messaged to the market previously. After we submit the IND, we anticipate that the FDA will spend some time looking at it. We’re a first-in-class product, and we’re going into the human coronary system. So we expect that there will be some review time. But once they approve that, and I certainly anticipate that they will, then we would start our clinical trial sometime in 2026. So everything is on track with what we’ve messaged to the marke
EX-31.1 4 huma-20250930x10qxex311.htm EX-31.1 Document Exhibit 31.1 CERTIFICATION I, Laura E. Niklason, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Humacyte, Inc. for the quarter ended September 30, 2025; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statement
Laura Niklason - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 Early life and education 2 Career 3 Philanthropy 4 Awards and honors 5 Publications 6 References Toggle the table of contents Laura Niklason Add languages Add links Article Talk English Read Edit View hist … ch. [ 24 ] 2021: Winner of Triangle Business Journal 2021 Life Sciences Award. Award went to Humacyte, Inc., of which Niklason is the founder. [ 25 ] 2020: National Academy of Engineering Member [ 8 ] 2017: Named to Fortune's Digital Health Care Leaders list for her work in regenerative medicine. [ 5 ] 2017: Cotlove Lectureship Award in Laboratory Medicine [ 26 ] 2017: Inducted into Women in Technology Hall of Fame [ 27 ] 2016: … hnology Hall of Fame [ 27 ] 2016: Named to 2016 Disruptor 50 Companies. Award went to Humacyte, Inc., of which Niklason is the founder. [ 28 ] 2015: Winner of FierceMedicalDevices 2016 Fierce 15. Award went to Humacyte, Inc., of which Niklason is the founder. [ 29 ] 2014: National Academy of Inventors Fellow [ 6 ] 2011: Winner of Popular Mechanics Breakthrough Innovators Award for 2011, for development of "off-the-self" tissue engineered vascul … elf" tissue engineered vascular graft to treat patients with vascular disease . Award went to Humacyte, Inc., of which Niklason is the founder. [ 30 ] 2011: Winner of Frost & Sullivan Growth, Innovation & Leadership Award 2011, for development of engineered vascular graft. Award went to Humacyte, Inc., of which Niklason is founder. 2010: 50 best inventions of 2010 (engineered lung) Time [ 4 ] 2008: College of Fellows, American Institute for Medical and … d Biological Engineering (AIMBE) [ 31 ] 2002: Beeson Physician Scholars Award, American Federation for Aging Research 2001: One of 21 U.S. News & World Report Innovators for 2001 2001: Hunt scholar, Pratt School of Engineering , Duke University 2000: Discover magazine award for technological innovation (finalist in the health category
Leadership - Humacyte Global, Inc. { link.addEventListener('click', function(event) { if (event.target.tagName === 'A') { const url = new URL(event.target.href); const isNotSymvess = !url.hostname.includes('symvess.com'); const isHumacyte = url.hostname.includes('humacyte.com') || url.hostname.includes('humacyte.test') || url.hostname.includes('hncdigital.com'); if (!isHumacyte && isNotSymvess) { event.preventDefault(); self.attemptedLink = event.target.href; self.externalLink = true; } } }); }); }, proceed() { window.open(this.attemptedLink, '_blank'); } }" class="wp-singular page-template-de … training in the US in internal medicine and pediatrics, followed by a clinical fellowship in endocrinology at the NIH. Sabrina Osborne, GPHR, SPHR, CPC Chief People Officer Ms. Osborne brings over 25 years of experience in Human Resources, Leadership, and Organizational Development within the Life Sciences industry. Her extensive management background, both within and outside of the HR function, equips her with the unique ability to balance business objectives with the needs … r from 2013 until his retirement from Deloitte in 2022. General Green completed residency training in both family practice and aerospace medicine and holds a B.S. from the University of Wisconsin–Parkside, an M.D. from the Medical College of Wisconsin, and an M.P.H. from the Harvard School of Public Health. Keith Anthony (Tony) Jones, M.D. Dr. Jones, the Alfred Habeeb Professor of Anesthesiology and Perioperative Medicine, is President of UA Health Services Foundation, Chief … l physiology, Dr. Jones joined the Mayo Clinic faculty in 1991 after completing residency and postgraduate work there, including a postdoctoral National Institutes of Health research fellowship. He served as program director of Mayo’s Smooth Muscle Physiology Laboratory and was promoted to the rank of professor in 2004. In addition to his many teaching, mentorship, and clinical activities, Dr. Jones is a prolific researcher with interests centering on the cellular and biochem … Chicago and an M.D. from the University of Michigan. Dr. Niklason completed her residency training in anesthesia and intensive care unit medicine at Massachusetts General Hospital and post-doctoral scientific training at the Massachusetts Institute of Technology in the laboratory of Dr. Robert Langer. Todd M. Pope Mr. Pope is a Partner at Revival
Humacyte ends $60M ATM, posts early Symvess sales | HUMA 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & … d to a potential joint venture and license, and filed a Marketing Authorization Application in Israel for Symvess in vascular trauma. The company also released an investor presentation and updated its risk factors to reflect ongoing losses, funding needs, regulatory and clinical trial uncertainties, pricing pressures and data-privacy compliance risks. Positive None. Negative None. Insights Biotech equity analyst neutral Humacyte pairs early Symvess revenue with new ex‑US init … negotiations toward a joint venture and license, and a Marketing Authorization Application in Israel for vascular trauma, point to early geographic broadening of the platform. Updated risk factors highlight substantial accumulated deficits, the need for additional capital, clinical and regulatory uncertainty, reimbursement and pricing pressure, and complex data‑privacy obligations. Overall, the disclosure blends incremental commercial progress with continued financing and ex … Company.   On March 16, 2026, the Company filed a Marketing Authorization Application (“MAA”) with the Ministry of Health of the State of Israel for approval of Symvess for the vascular trauma indication. In response to requests from surgeons, the Company is also pursuing methods of making Symvess available on a hospital-by-hospital basis in advance of any future MAA approval in Israel.   Risk Factor Updates   The Company has provided certain updat … among the Company, Humacyte Global, Inc., and Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders and as lender (the “Loan Agent”) , the Common Stock Purchase Agreement, dated as of September 24, 2024, with Lincoln Park Capital Fund, LLC and, to a lesser extent, through gr
Humacyte, Inc. (HUMA) 8-K Earnings Release, Other Events - Mar 2026 HOME LOGIN PREMIUM SEC FILINGS FREE TRIAL API FOOTNOTED STOCK SCREENERS EARNINGS TRENDING INSIDER TRADING MANAGER PORTFOLIOS SENTIMENT ANALYSIS LATE NT SEC FILINGS Humacyte, Inc. (HUMA) SEC Filing 8-K Material Event for the period ending Thursday, March 19, 2026 Home SEC Filings Humacyte, Inc. (HUMA) 8-K Material Event Thu Mar 19 2026 SEC Filings HUMA Valuations Intrinsic Value Financial Stability Financial Ratios Insider Trades Manager Portfolios Historical Financials (CSV) Notifications HUMA Annual Reports 10-K Annual
Humacyte Phase 3 ATEV Study Meets Primary Endpoint | HUMA 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & … ow-up will continue, and Humacyte plans to file a supplemental Biologic License Application with the FDA in the second half of 2026 for high-risk end-stage kidney disease patients. Positive Phase 3 efficacy success: ATEV met the V012 primary endpoint with 220 catheter-free days versus 129 for AV fistula (91-day advantage, p=0.00070), a potentially transformative result in a high-need dialysis access population and a basis for a planned supplemental BLA filing in the second ha … nmet-need population. The company plans to file a supplemental Biologic License Application in the second half of 2026 for adult end-stage kidney disease patients at increased risk of fistula maturation failure. Future regulatory decisions and longer-term follow-up from the up to 150-patient V012 study will be key to understanding commercial potential. 8-K Event Classification 2 items: 8.01, 9.01 2 items Item 8.01 Other Events Other Voluntary disclosure of events the company … Terms acellular tissue engineered vessel, catheter-free days, Biologic License Application, Regenerative Medicine Advanced Therapy (RMAT) designation, +2 more 6 terms acellular tissue engineered vessel medical "results from its Phase 3 clinical trial (V012) of the acellular tissue engineered vessel (ATEV)" Acellular tissue engineered vessels are lab-made replacement blood vessels created from biological materials but manufactured without living cells, so they act like a read … endpoint and was observed to have superior catheter-free days" Biologic License Application regulatory "Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration" A biologic license application is a formal regulatory submission seeking permission to market a biological medicine—such as a vaccin
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access May 26, 2026 | 8 min read Twitter LinkedIn Facebook Email Print - Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The AT … TEV over AV fistulas. Subject to results from the V012 study, Humacyte plans to submit a supplemental Biologics License Application (sBLA) for a second indication in AV access for hemodialysis during the second half of 2026. For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency. About Humacyte Humacyte, Inc. (Nasdaq: HUMA) is developi … nge of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, ped … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Revolutionizing Treatment: Our Contribution to Humacyte’s Latest Innovation - Atlantic Research Group Need Help? Chat Now With a Live Representative! Expertise Oncology Immunology Neurology Services Signature Services Clinical Operations Medical Monitoring Biostatistics Quality Assurance Data Management Drug Safety Technologies Unique Services Decentralized Trials Rescue Studies Retrospective Studies Legal Representation REQUEST CAPABILITIES PRESENTATION About About Leadership Careers Resources Contact Us Revolutionizing Treatment: Our Contribution to Humacyte’s Latest Innovation Revolutionizi … . | Terms and Conditions | Privacy Policy | Web Maintained by TechArk GO TO TOP Submit --> Atlantic Research Group has now merged with Evestia Clinical to create a leading global specialist CRO. The highly experienced and globally recognized leadership team at Evestia Clinical is building a world-class specialist CRO provider and we are excited to bring across our whole team on this journey. We are pleased that our customers will be able to benefit from this seamless continui
--> Humacyte CEO Laura Niklason updates us on the early days of the launch of Symvess, the company's bioengineered blood vessel product top of page Home Quick Takes Around Kendall Science Spotlight BiotechTV U Company News Bright Minds Shows Biotech Direct BioVenture VoiCes Biotech CEO Sisterhood The Studio at Kendall Square Off-Target Effects with Matt Gline Tech + Tours Humacyte CEO Laura Niklason updates us on the early days of the launch of Symvess, the company's bioengineered blood vessel product Sep 8, 2025 1 min read She describes the work the company is doing with hospitals and th
Humacyte charts IPO via merger with special purpose acquisition company | 2021-02-17 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China
Humacyte, Inc. (HUMA): akcionáři, držitelé, insider trading AI Nástroje Kaledář zisků Super investoři Connector Ceník Registrace Přihlášení Zkusit zdarma Humacyte, Inc. HUMA Cena: Valuace 85 Růst 68 Zdraví 75 Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři Akcionáři Akcionáři společnosti Insider trading Akcionáři společnosti Držitel Počet akcií Podíl společnosti Změna % Váha pozice v portfoliu Prvně nakoupeno BLACKROCK, INC. 12.3 mil 7.79 … 2022-09-30 JUMP FINANCIAL, LLC 93.76 tis 0.08% -0.03% 0.01% 2024-06-30 VERITION FUND MANAGEMENT LLC 90.24 tis 0.08% 0.00% 0.00% 2024-06-30 PRICE T ROWE ASSOCIATES INC /MD/ 112.17 tis 0.07% 0.00% 0.00% 2023-03-31 COMMONWEALTH EQUITY SERVICES, LLC 83.13 tis 0.07% 0.00% 0.00% 2024-03-31 CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 81.81 tis 0.07% 0.00% 0.00% 2021-12-31 MILLENNIUM MANAGEMENT LLC 108.15 tis 0.07% 0.00% 0.00% 2022-03-31 LEGAL & GENERAL GROUP PLC 81.41 tis 0.07% 0.00 … 0% 0.00% 2023-12-31 CWM, LLC 97.87 tis 0.06% 0.00% 0.00% 2024-06-30 DIMENSIONAL FUND ADVISORS LP 62.24 tis 0.06% 0.00% 0.00% 2023-09-30 THOMPSON SIEGEL & WALMSLEY LLC 92.00 tis 0.06% 0.00% 0.00% 2024-12-31 SEI INVESTMENTS CO 93.05 tis 0.06% 0.00% 0.00% 2026-03-31 INTEGRATED ADVISORS NETWORK LLC 86.78 tis 0.06% 0.01% 0.01% 2025-09-30 ENGINEERS GATE MANAGER LP 84.96 tis 0.05% 0.00% 0.00% 2025-12-31 CITIGROUP INC 82.54 tis 0.05% 0.00% 0.00% 2021-09-30 BREVAN HOWARD CAPITAL MANAG … NG, LLC 40.03 tis 0.04% 0.00% 0.00% 2023-09-30 NEW YORK STATE COMMON RETIREMENT FUND 36.12 tis 0.03% 0.00% 0.00% 2022-06-30 MANUFACTURERS LIFE INSURANCE COMPANY, THE 34.92 tis 0.03% 0.00% 0.00% 2022-12-31 AMERICAN INTERNATIONAL GROUP, INC. 30.18 tis 0.03% 0.00% 0.00% 2022-06-30 VOYA INVESTMENT MANAGEMENT LLC 29.67 tis 0.03% 0.00% 0.00% 2022-12-31 TOWER RESEARCH CAPITAL LLC (TRC) 27.91 tis 0.03% 0.00% 0.00% 2021-12-31 IMPRINT WEALTH LLC 23.32 tis 0.02% -0.08% 0.02% 2023-03-31 … 0 8.12 2025 0 Niklason Laura E director, officer: President, CEO and Director A-Award 311100 1.23 17.11 2025 311100 Dougan Brady W director A-Award 311100 1.23 17.11 2025 311100 Parikh Shamik J officer: Chief Medical Officer A-Award 311100 0.00 17.11 2025 318600 Sander Dale A. officer: CFO and Chief Corp. Deve. Off. A-Award 311100 0.00 17.11 2025
Humacyte Stock (HUMA) Opinions on Recent Price Surge | Quiver Quantitative --> Skip to Main Content MEMORIAL DAY API SALE 50% off your first year of Quiver API ... Use Promo Code: MEM50 Quiver API --> × Get a Free Trial on Quiver Premium Today! Upgrade Now Upgrade × Get Email Alerts On HUMA Stock Enter your email to receive free breaking news alerts and insights related to HUMA. Sign Up Now (Free) Home Datasets Most Popular Politician Search Congress Trading 2026 Midterm Elections Donald Trump Stock Trades Election Fundraising Insider Trading Government Contracts Corporate Lobbying … e's insider trading dashboard. Receive $HUMA Data Alerts Sign Up Humacyte Hedge Fund Activity We have seen 58 institutional investors add shares of Humacyte stock to their portfolio, and 77 decrease their positions in their most recent quarter. Here are some of the largest recent moves: CENTERBOOK PARTNERS LP removed 3,146,628 shares (-91.7%) from their portfolio in Q3 2025, for an estimated $5,475,132 STATE STREET CORP removed 1,983,068 shares (-45.2%) from their portfolio i
Humacyte CEO Dr. Laura Niklason to Present at J.P. Morgan Healthcare Conference January 11 Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos A … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Senior Quality Systems Specialist in Durham at Humacyte | Apply now! – StudySmarter – Talents Everything for your career Find a job Senior Quality Systems Specialist in Durham Apply Now Apply Now Job Board Companies Humacyte Senior Quality Systems Specialist Senior Quality Systems Specialist in Durham Durham Full-Time 72000 - 108000 $ / year (est.) No home office possible Apply Now Apply Now H At a Glance Tasks: Oversee quality management systems and ensure compliance with GMP regulations. Company: Leading biotechnology company in Durham, NC, focused on innovation. Benefits: Competitive compen … haring your experiences on platforms like ResearchGate to enhance visibility. ✨ Apply Directly On Company Websites When you find a company you're excited about, like Humacyte, go directly to their careers page and apply. Many biotech firms prefer to source candidates from their own sites. Also, it shows initiative and that you’re serious about joining the team! We think you need these skills to ace Senior Quality Systems Specialist in Durham Quality Management Systems GMP … oblem-Solving Skills Communication Skills Project Management Some tips for your application 🫡 Showcase Your Scientific Skills: When applying for a full-time role in biotechnology, it's crucial to highlight your relevant scientific skills and experience. Include specific techniques or technologies you've worked with, like CRISPR or mass spectrometry, in your CV. This way, we can see that you have the hands-on experience necessary for the position at Humacyte. Tailor Y … ring cross-functional team initiatives. This can make a huge difference in your application quality. How to prepare for a job interview at Humacyte ✨ Showcase Your Technical Know-How In biotechnology, it's crucial to demonstrate a strong grasp of relevant techniques and tools—so be prepared to discuss the lab methods you've used or any specific projects you’ve been part of. Bring along any data or results that highlight your contributions; we want to see how you can a … and grow. Senior Quality Systems Specialist in Durham Humacyte Location: Durham Apply Now Apply Now Company Login About Us Product Exams Explanations Magazine Help Help Center Premium Login © Vaia Terms Privacy
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer - GeneOnline News Skip to content Advertise Inquiries | About Us | | Events Subscribe Intelligence Menu Toggle Markets & Deals Policy & Regulation Ranking & Reports Founders’ Circle Development to Market Discovery Menu Toggle R&D Frontiers Trials & Approvals CDMO & CRO Activity Public Health Oncology Insights Infection, Immunity & Vaccination Nexus Menu Toggle AI, Tech & Digital Innovation Advanced Biologics & Biosimilars Exosomes & Delivery Precision Medicines Cell, Gene & Regen
Humacyte - Recently WITI has been reposting some powerful... Facebook Вход Публикация Humacyte Humacyte 30 июль 2024 г. · Поделился/-ась с Доступно всем Recently WITI has been reposting some powerful content from their Hall of Fame archives. WITI had inducted our CEO, Dr. Laura Niklason, which is a milestone that speaks volumes about her leadership at Humacyte. Her pioneering work not only shapes our mission but inspires all who dream big. #WITI #Innovation #Leadership #Biotech #regenerativemedicine #Humacyte https://fb.watch/t5l8Ekt0mO/ Все реакции: 9 2 комментария Поделились: 3 Поставить &qu